Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network

Reek, J.M.P.A. van den; Lüumig, P.P.M. van; Otero, M.E.; Zweegers, Jeffrey; Kerkhof, P.C.M. van de; Ossenkoppele, P.M.; Njoo, M. D.; Mommers, J.M.; Koetsier, M.I.A.; Arnold, W.P.; Sybrandy-Fleuren, B.A.M.; Kuijpers, A.L.A.; Andriessen, M.P.M.; Seyger, M.M.B.; Kievit, Wietske; Jong, E.M.G.J. de

doi:10.1111/bjd.12862

Cited by 29 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High impact of the treatment modality on satisfaction scores and greatest satisfaction with biologicals were confirmed in regression models controlling for several confounding factors. These results are well in line with several other studies (2,11,12,14,(20)(21)(22) and may be attributed to the high efficacy, favourable risk-benefit profile and convenient application mode of biologicals.…”

Section: Discussionsupporting

confidence: 91%

Treatment Satisfaction of Patients with Psoriasis

Schaarschmidt¹,

Kromer²,

Herr³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

Treatment satisfaction of patients with psoriasis largely depends on the treatment modality, but evidence on preferences for specific medications is scarce. Here we assessed treatment satisfaction of 200 participants with moderate-to-severe psoriasis from a German University hospital with a 5-point scale and the Treatment Satisfaction Questionnaire for Medication (TSQM) and determined sociodemographic and disease-related influence factors. Participants obtaining biologicals and traditional systemic medications were significantly more satisfied than those receiving phototherapy or topical agents (TSQM = 323.3, 288.0, 260.6 or 266.8; p < 0.001). The highest TSQM score was calculated for ustekinumab (350.1), followed by acitretin (338.1), adalimumab (323.0), fumaric acid esters (304.7), infliximab (300.2), etanercept (298.8), and methotrexate (272.3; p < 0.001). High disease-related quality of life impairment (β = -0.437, p < 0.001) and psoriatic arthritis (β = -0.185, p = 0.005) were associated with decreased satisfaction. Optimising satisfaction is essential to improve adherence and outcome. We show high preferences for biologicals, particularly ustekinumab, but also good satisfaction with certain traditional medications.

show abstract

Section: Discussionsupporting

confidence: 91%

Treatment Satisfaction of Patients with Psoriasis

Schaarschmidt¹,

Kromer²,

Herr³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…Similarly, Ragnarson Tennvall et al37 described the highest treatment satisfaction, that is, 8.2 (scale of 0 not at all satisfied to 10 very satisfied) in patients who had been treated with biological drugs for 12 months, followed by patients who received systemic treatment for less than 12 months (6.5) and patients receiving topical treatment (5.7). Van den Reek et al38 confirmed the high satisfaction rates achieved with biologic treatment, with statistically significant ( P <0.05) improvements in the “efficacy”, “convenience” and “global satisfaction” domains of TSQM after 3 and 6 months initiation of biologic therapy.…”

Section: Resultsmentioning

confidence: 86%

Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature

Belinchón¹,

Rivera²,

Blanch³

et al. 2016

PPA

View full text Add to dashboard Cite

Background and objectiveAdherence to treatment in patients with psoriasis is often poor. An investigation of patient preferences and satisfaction with treatment may be important, based on the expected correlation with therapy compliance. This paper aims to examine and describe the current literature on patient preferences, satisfaction and adherence to treatment for psoriasis in the European Union (EU).MethodsElectronic searches were conducted using PubMed, ISI Web of Knowledge, Scopus, Spanish databases and Google Scholar. European studies published in English or Spanish between January 1, 2009 and December 31, 2014 regarding patient-reported outcomes in psoriatic patients were included. Studies conducted in non-EU countries, letters to the editor, editorials, experts’ opinions, case studies, congress proceedings, publications that did not differentiate between patients with psoriasis and psoriatic arthritis or studies related to specific treatment were excluded.ResultsA total of 1,769 titles were identified, of which 1,636 were excluded as they were duplicates or did not provide any relevant information. After a full-text reading and application of the inclusion/exclusion criteria, 46 publications were included. This paper will describe publications on adherence (n=4), preferences (n=5) and satisfaction with treatment (n=7). Results related to health-related quality of life articles (n=30) have been published elsewhere. Adherence rates are generally low in psoriasis patients regardless of the type of treatment, severity of disease or methods used to measure adherence. Biologic therapy is associated with greater clinical improvement. There is a direct association between physician recommendations, patient preferences and several domains of treatment satisfaction.ConclusionThe results of this review support the conclusion that adherence rates in patients with psoriasis are suboptimal and highlight the need to improve patient compliance and satisfaction with treatment. Patients’ preferences should be taken into account in the treatment decision-making process in order to improve patients’ clinical outcomes by ensuring satisfaction and adherence.

show abstract

“…Similarly, TNF-a is so deeply involved in psoriasis development that the therapeutic management of patients has radically changed, following the introduction of TNF-a inhibitors [10,33,38]; thus, its overexpression in MSCs was expected.…”

Section: Discussionmentioning

confidence: 99%

Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis

et al. 2014

View full text Add to dashboard Cite

The expression of genes encoding for Th1, Th2 and Th17 cytokines has been extensively evaluated in differentiated skin cells of psoriatic patients. The microenvironment exerts a control on the phenotype of resident mesenchymal stem cells (MSCs) into the skin of psoriasis patients. Aim of the study was to extensively evaluate the relative expression of 43 genes encoding for Th1, Th2 and Th17 cytokines in MSCs isolated from skin of psoriasis patients. MSCs resident into psoriatic skin were isolated, characterized and profiled by PCR array for the relative expression of genes encoding for cytokines involved in Th1, Th2 and Th17 pathways. MSCs isolated from the skin of healthy subjects were used as control. The MSCs isolated from skin of psoriasis patients showed a greater relative expression of the most part of the analyzed genes encoding for Th1 and Th17 cytokines: INF-γ, CCR5, CXCL9, CXCL10, IL6, IL8, TNF-α, IL23A, CCL2, CCL20, CXCL2, CXCL5, IL17C, IL17F, IL17RA, IL21, TLR2 than healthy subjects. On the contrary, the relative expression of genes encoding for Th2 cytokines: CCL1, CCL22, CXCL12, IL2, IL3, IL4, IL13B, IL 22, IL 27, TGF-β1, was similar between the MSCs isolated from psoriasis and healthy subjects. In conclusion, the MSCs isolated from psoriasis show an imbalance between the Th1-Th17 and Th2 pathways, which reflects the well-known abnormal balance observed in differentiated skin cells. This evidence could strengthen the hypothesis of an early involvement of resident MSCs in the pathogenesis of psoriasis.

show abstract

Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network

Abstract: CorrespondenceJuul M.P.A. van den Reek.

Cited by 29 publications

References 23 publications

Treatment Satisfaction of Patients with Psoriasis

Treatment Satisfaction of Patients with Psoriasis

Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature

Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis

Contact Info

Product

Resources

About